Atogepant is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, particularly developed for migraine prevention, to receive FDA approval, stated AbbVie.

The drug received approval for prevention of episodic migraine in adults. It has become the second gepant to be approved for migraine prevention. Rimegepant, which was initially approved for the treatment of acute migraine, bagged an additional indication for prevention of migraine this year.

Atogepant has a high affinity at the CGRP receptor and unlike the injectable anti-CGRP monoclonal antibodies for migraine prevention, including erenumab, fremanezumab, galcanezumab, and eptinezumab, atogepant as well as the other gepants are small-molecule medications that can be administered orally… (Medpage Today)